60+ Leading Graft Versus Host Disease Pipeline Companies are working to improve the Treatment Landscape

60+ Leading Graft Versus Host Disease Pipeline Companies are working to improve the Treatment Landscape

DelveInsight’s, “Graft versus host disease Pipeline Insight, 2023,” report provides comprehensive insights about 60+ Graft Versus Host Disease companies and 60+ pipeline drugs in Graft versus host disease pipeline landscape. It covers the Graft Versus Host Disease pipeline drug profiles, including Graft Versus Host Disease clinical trials and nonclinical stage products. It also covers the Graft Versus Host Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Graft versus host disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Graft versus host disease clinical trials studies, Graft versus host disease NDA approvals (if any), and product development activities comprising the technology, Graft versus host disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Graft versus host disease Pipeline Insight Report

 

  • DelveInsight’s Graft versus host disease pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for Graft versus host disease treatment.

 

  • The leading Graft versus host disease Companies includes Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology,   AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others.

 

  • Promising Graft versus host disease pipeline therapies includes Itolizumab, MC 0518, MaaT013, Inolimomab, PG101, Axatilimab, ASC930, SCM CGH, Alpha galactosylceramide liposomal, Obinutuzumab, Apraglutide, TQ 05105, Efavaleukin alfa, Glasdegib, Arsenic trioxide, LIS1, TQ 05105,  T-Guard, Neihulizumab, Natalizumab, EQ001, CD24-Fc,  ApoGraft, Acalabrutinib, BMS-986004, DT 202, Pacritinib, OSSM-001, OrcaGraft, SYN-004,  CK 0805, CPI 818, Research programme: human embryonic stem cell based therapeutics, RHX-317, CB 103, Efmarodocokin Alfa,  Lenzilumab, Alpha-1 antitrypsin (AAT), Begesand, and others.

 

  • The Graft versus host disease companies and academics are working to assess challenges and seek opportunities that could influence R&D Graft versus host disease (GVHD). The Graft versus host disease pipeline therapies under development are focused on novel approaches for Graft versus host disease (GVHD) treatment.

 

To explore more information on the latest breakthroughs in the Graft versus host disease Pipeline treatment landscape of the report, click here @ Graft versus host disease Pipeline Outlook

 

Graft versus host Disease Overview

Graft-versus-host disease (GvHD) is a systemic disorder that occurs when the graft’s immune cells recognize the host as foreign and attack the recipient’s body cells. “Graft” refers to transplanted, or donated tissue, and “host” refers to the tissues of the recipient. It is a common complication after allogeneic hematopoietic stem cell transplant (HCT). Cells of the immune system are trained early to differentiate between “”self”” cells and “”non-self”” cells. The ability to recognize “”non-self”” cells depends on a set of genes knows as the histocompatibility genes that provide instructions for making a group of related proteins known as major histocompatibility complex (MHC proteins) or human leukocyte antigens (HLA).

 

Recent Developmental Activities in the Graft Versus Host Disease Treatment Landscape

  • In October 2022, Mesoblast Limited announced that it had submitted to the U.S. Food and Drug Administration (FDA) substantial new information on clinical and potency assay items identified in the Complete Response Letter (CRL) received from FDA in September 2020 to the Biologics License Application (BLA) for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).
  • In August 2022, Johnson & Johnson and AbbVie’s Imbruvica gained FDA approval for kids ages 1-11 with chronic graft-versus-host disease. It is the first treatment option for this age group. The FDA first signed off on Imbruvica’s use for those 12 and older with cGVHD in 2017.
  • In June 2022, Xenikos B.V. announced the enrollment of the first patient in a global pivotal Phase III clinical study designed to evaluate T-Guard versus ruxolitinib for treating patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT).
  • In May 2022, Novartis announced the European Commission (EC) had approved Jakavi (ruxolitinib) for treating patients aged 12 years and older with acute or chronic GvHD who have an inadequate response to corticosteroids or other systemic therapies.The approval of Jakavi follows the positive opinion granted in March by the Committee for Medicinal Products for Human Use of the European Medicines Agency, based on the Phase III REACH2 and REACH3 trials in which Jakavi demonstrated superiority in overall response rate (ORR) compared to best available therapy (BAT).
  • In March 2022, VectivBio Holding AG  announced that it had entered two agreements that would strengthen the company’s balance sheet and expand apraglutide’s commercial potential beyond VectivBio’s core markets in the US and EU. The company entered into an exclusive licensing agreement with Asahi Kasei Pharma Corporation to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for treating short bowel syndrome with intestinal failure (SBS-IF), steroid-refractory acute graft-versus-host disease (aGVHD) and future indications in Japan.
  • In March 2022, Equillium commenced the Phase III EQUATOR clinical trial of itolizumab to treat acute graft-versus-host disease (aGVHD) patients.The placebo-controlled, randomized, multicentre, double-blind trial will compare the safety and efficacy of intravenous doses of itolizumab against placebo as a first-line treatment for aGVHD plus corticosteroids.

 

For further information, refer to the detailed Graft Versus Host Disease Unmet Needs, Graft Versus Host Disease Market Drivers, and Graft Versus Host Disease Market Barriers, click here for Graft Versus Host Disease Ongoing Clinical Trial Analysis

 

Graft versus host disease Emerging Drugs Profile

 

Teplizumab: Prevention Bio

MaaT013 is a full-ecosystem, off-the-shelf, standardized, pooled-donor, Microbiome Ecosystem Therapy. It is characterized by a consistently high diversity and richness of microbial species and the presence of ButycoreTM (group of bacterial species known to produce anti-inflammatory metabolites). MaaT013 aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and thus reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

ASC930: ASC Therapeutics

ASC930 is an allogeneic cell therapy based on off-the-shelf Decidua Stromal Cells obtained from the fetal membrane of the maternal placenta for the treatment of acute steroid-refractory Graft-versus-Host Disease, a common complication of patients receiving allogeneic hematopoietic stem cell transplantation to treat hematologic conditions. ASC930 cells possess potent immunosuppressive properties and do not display any differentiation potential, making them an ideal immunoregulatory cell therapy.

 

Graft Versus Host Disease Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the Graft versus host disease (GVHD) therapies. The GVHD companies which have their  drug candidates in the most advanced stage, i.e preregistration include ElsaLys Biotech.

 

Request a sample and discover the recent advances in Graft Versus Host Disease Ongoing Clinical Trial Analysis and Medications, click here @ Graft Versus Host Disease Treatment Landscape

 

Scope of the Graft Versus Host Disease Pipeline Insight Report

  • Coverage- Global
  • Graft versus host disease Companies- Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Medsenic, Xenothera, Xenikos, AltruBio Inc., Biogen, OncoImmune, Inc., Cellect Biotechnology,   AstraZeneca, Bristol-Myers Squibb, Dystrogen Therapeutics, CTI BioPharma, Ossium Health, Inc., Orca Biosystems, Inc., Synthetic Biologics Inc., Cellenkos, Corvus Pharmaceuticals, ImStem Biotechnology, Rheos Medicines, Equillium, Cellestia Biotech, Genentech, Humanigen, CSL Behring, ADIENNE, and others.
  • Graft versus host disease pipeline therapies includes Itolizumab, MC 0518, MaaT013, Inolimomab, PG101, Axatilimab, ASC930, SCM CGH, Alpha galactosylceramide liposomal, Obinutuzumab, Apraglutide, TQ 05105, Efavaleukin alfa, Glasdegib, Arsenic trioxide, LIS1, TQ 05105,  T-Guard, Neihulizumab, Natalizumab, EQ001, CD24-Fc,  ApoGraft, Acalabrutinib, BMS-986004, DT 202, Pacritinib, OSSM-001, OrcaGraft, SYN-004,  CK 0805, CPI 818, Research programme: human embryonic stem cell based therapeutics, RHX-317, CB 103, Efmarodocokin Alfa,  Lenzilumab, Alpha-1 antitrypsin (AAT), Begesand, and others.
  • Graft versus host disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Graft Versus Host Disease Market Drivers and Graft Versus Host Disease Market Barriers, click here @ Graft Versus Host Disease Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Graft versus host disease (GVHD): Overview
  4. GVHD Pipeline Therapeutics
  5. Graft versus host disease Therapeutic Assessment
  6. Graft versus host disease (GVHD)– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Itolizumab: Biocon
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ASC930: ASC Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. TQ 05105: Chia Tai Tianqing Pharmaceutical Group
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Graft versus host disease (GVHD) Key Companies
  21. Graft versus host disease (GVHD) Key Products
  22. Graft versus host disease (GVHD) Unmet Needs
  23. Graft versus host disease (GVHD) Market Drivers and Barriers
  24. Graft versus host disease (GVHD) Future Perspectives and Conclusion
  25. Graft versus host disease (GVHD) Analyst Views
  26. Appendix

 

Got Queries? Find out the related information on Graft Versus Host Disease Mergers and acquisitions, Graft Versus Host Disease Licensing Activities @ Graft Versus Host Disease Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: